NewsRoom Articles - Page 16 of 50

WednesdayFeb 21, 2024 9:00 am

Diamond Lake Minerals Inc. (DLMI) Sees Fractional STO Ownership as a Solution to Real Estate Market Volatility and Insecurity

Utah-based Diamond Lake Minerals is developing its vision of an umbrella parent company that not only holds a variety of industry-crossing subsidiaries, but that also serves as a gateway for cautious investors looking to dip a toe into digital assets The company’s vertically integrated portfolio will include holdings that are infused with security token offerings registered with the U.S. Securities and Exchange Commission Diamond Lake views its digital asset-in-a-real world asset gateway as a hedge against market volatility, especially for real estate properties that may be over-leveraged and struggling to stay afloat while seeking favorable lending terms A recent spate…

WednesdayFeb 21, 2024 8:50 am

GEMXX Corp. (GEMZ) to Capitalize on Growing Trend in India’s Jewelry and Colored Gemstone Markets

GEMXX recently announced insights into the burgeoning jewelry and colored gemstones markets in India The jewelry market in India is expected to grow by US$21.54 billion between 2023 and 2027, while the colored gemstones market is projected to reach $1.9 billion by 2033 from an estimated $707.8 million in 2024 GEMXX, a leading producer of top-quality finished Ammolite, anticipates that this rare gemstone has the potential to attract a significant portion of buyers in India seeking something innovative or distinct from conventional colored gemstones The company is positioned to capitalize on the growing trend in the colored gemstones market, with…

TuesdayFeb 20, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a…

TuesdayFeb 20, 2024 9:00 am

Mullen Automotive Inc. (NASDAQ: MULN) Displays Vehicles for First Time at CES, Unveils Newest EV Offering

Mullen debuted its FIVE RS at this year’s CES show in Las Vegas Several car and auto publications reported on the unveiling of the new model Mullen anticipates beginning production of the FIVE RS in late 2025, with sales commencing in mid-2026 For the first time ever, Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, exhibited its line of commercial and consumer EVs at the Consumer Electronics Show(R) (“CES”) in Las Vegas. In addition to displaying its line of vehicles, the company also debuted its high-performance EV crossover, the Mullen FIVE RS; the world debut of the new vehicle…

FridayFeb 16, 2024 9:45 am

Vision Marine Technologies Inc. (NASDAQ: VMAR) Spotlighted in Article Touting Promising Boat Stocks

“In the dynamic world of investments, electric boat stocks are gaining momentum,” reports InvestorPlace The article calls Vision Marine a key player in the electric boat stocks market VMAR’s recent partnerships, market expansion and production enhancements point to potential growth and innovation As investors pay increasing attention to potential involvement in clean, green-energy companies, the idea of sustainability is becoming more of a priority in sectors across the board. Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating industry, is capturing attention and was recently spotlighted in an InvestorPlace article titled “Three Electric…

WednesdayFeb 14, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial

Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”)…

TuesdayFeb 13, 2024 9:45 am

GEMXX Corp. (GEMZ) Anticipates Significant Growth over the Next 24 Months on ‘Tremendous Potential’ in Ammolite and Gold Markets

GEMXX expects the growing demand for Ammolite, coupled with the positive outlook for gold prices, to support significant growth over the next 24 months Last year, GEMXX moved to complement its Ammolite operations with the purchase of gold assets in Canada The price of gold has held steady above US$2,000 per ounce, coming off a record-breaking 2023 when it rallied to a record-high year-end close The future looks promising for gold because it is projected to reach new highs in the coming months, according to GEMXX The price of an ounce of gold rallied to a record high year-end close…

MondayFeb 12, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter

Lexaria, a global innovator in drug delivery platforms, just announced ambitious plans for the 2024 calendar year The letter confirms that the 2024 plans have been made possible by significant strides that were made by the company in 2023 Lexaria looks to build on the momentum gained from the previous year, ultimately asserting market dominance and making 2024 its best year yet Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its ambitious plans for the 2024 calendar year. In his annual letter, Chris Bunka, Lexaria’s CEO, noted that this would mark the year that will…

MondayFeb 05, 2024 11:15 am

Diamond Lake Minerals Inc. (DLMI) Emphasizes Regulatory Safety Framework While Building Bridge to Digital Asset Investments

Traditional investors often hold onto real world assets (“RWAs”) with the expectation that their risk factors are known and manageable, while avoiding digital assets because of potential volatility and uncertainty about what actually underpins their risk factors Utah-based Diamond Lake Minerals Inc. is building a vertically integrated portfolio of noteworthy subsidiaries that will be infused with security token offerings as digital assets bridged to RWAs DLMI is working in conjunction with the U.S. Securities and Exchange Commission, SEC-registered digital asset exchange INX, to provide heightened security to digital offerings DLMI’s portfolio will include industry-agnostic holdings that span real estate, wireless…

ThursdayFeb 01, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R) The company’s chronic dosing animal study and its second human pilot study will commence in Spring and run for 12 weeks. The third human pilot study will start in May or June These studies will evaluate DehydraTECH for the improved…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000